NCT02514681 2025-09-10
PRECIOUS
Japan Breast Cancer Research Group
Phase 3 Completed
Clinical Trials
69 trialsNCT03242616 2025-04-17
PemVin vs Vin in Previously Treated Metastatic Breast Cancer
Seoul National University Hospital
Phase 2 Completed
NCT02892123 2024-11-27
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Jazz Pharmaceuticals
Phase 1 Completed
NCT03901339 2024-10-21
TROPiCS-02
Gilead Sciences
Phase 3 Completed
NCT03839823 2024-10-09
RIGHT Choice
Novartis
Phase 2 Completed
NCT03355157 2024-10-01
PADMA
GBG Forschungs GmbH
Phase 4 Completed
NCT03887130 2024-04-30
Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer
Pierre Fabre Medicament
Phase 2 Completed
NCT02954055 2024-02-26
METEORA-II
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT00128310 2023-05-31
Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients
Spanish Breast Cancer Research Group
Phase 3 Completed
NCT02915744 2023-04-14
ATTAIN
Nektar Therapeutics
Phase 3 Completed
NCT02574455 2022-06-15
ASCENT
Gilead Sciences
Phase 3 Completed
NCT01802970 2021-10-08
Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients
Baylor Research Institute
Phase 1 Completed
NCT01835236 2021-03-30
Trastuzumab & Pertuzumab Followed by T-DM1 in MBC
Swiss Cancer Institute
Phase 2 Completed
NCT00006682 2020-08-14
Vinorelbine and Docetaxel in Treating Women With Metastatic Breast Cancer
Medstar Health Research Institute
Phase 2 Completed
NCT01950182 2020-07-15
SYSUCC-002
Sun Yat-sen University
Phase 3 Completed
NCT02628613 2019-11-01
Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations
Fudan University
Phase 2 Completed
NCT01125566 2019-07-18
LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment
Boehringer Ingelheim
Phase 3 Completed
NCT00148681 2019-01-15
Preoperative Herceptin and Navelbine for Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01305941 2018-12-17
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT02802748 2018-09-20
Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA)
SOLTI Breast Cancer Research Group
Phase EARLY_PHASE1 Completed
NCT00266110 2018-09-12
Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT02619929 2018-08-29
StepUp
Pierre Fabre Pharma GmbH
Completed
NCT02225470 2018-08-28
Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
Eisai Inc.
Phase 3 Completed
NCT00706030 2018-08-09
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
Puma Biotechnology, Inc.
Phase 1/2 Completed
NCT00194779 2018-03-12
Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery
University of Washington
Phase 2 Completed
NCT01104259 2017-08-10
Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer
University of Washington
Phase 1 Completed
NCT01520103 2017-08-09
VicTORia
AIO-Studien-gGmbH
Phase 2 Completed
NCT01013740 2017-05-31
VITAL
Novartis
Phase 2 Completed
NCT01007942 2017-04-05
BOLERO-3
Novartis
Phase 3 Completed
NCT00093808 2017-03-06
Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00828074 2017-02-27
Sorafenib and Vinorelbine in Treating Women With Stage IV Breast Cancer
City of Hope Medical Center
Phase 1/2 Completed
NCT01565083 2016-11-22
VELVET
Hoffmann-La Roche
Phase 2 Completed
NCT01941771 2016-10-28
XeNa
University of Aarhus
Phase 2 Completed
NCT00868634 2016-08-31
CARIN
iOMEDICO AG
Phase 3 Completed
NCT00022152 2016-07-06
Vinorelbine in Treating Older Women With Stage IV Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01155258 2016-06-13
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
University of Southern California
Phase 1 Completed
NCT00193089 2015-12-10
Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01441596 2015-09-07
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
Boehringer Ingelheim
Phase 2 Completed
NCT01242449 2015-05-21
OVINTRA
Vejle Hospital
Phase 2 Completed
NCT00724386 2014-03-07
Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer
University of Chicago
Phase 1 Completed
NCT00513058 2014-01-14
Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer
UNICANCER
Phase 1 Completed
NCT00004237 2013-11-06
Comparison of Three Combination Chemotherapy Regimens in Treating Women With Stage I or Stage II Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00103233 2013-06-24
Vinorelbine With or Without Trastuzumab in Treating Women With Progressive Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00041067 2013-06-06
S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT00670982 2013-05-13
Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00148668 2013-04-09
Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00014430 2013-03-14
Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer
Dartmouth-Hitchcock Medical Center
Phase 1 Completed
NCT00153907 2013-02-07
Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT00017394 2013-01-17
Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01128543 2012-12-12
Lapatinib in Combination With Vinorelbine
GlaxoSmithKline
Phase 2 Completed